Results 221 to 230 of about 6,183 (280)

Letter to the Editor: Midodrine for Hepatic Hydrothorax

Hepatology, 2021
We read with interest the article by Banini et al.1 They have succinctly described the pathophysiology and management of hepatic hydrothorax. We would like to share a few thoughts on the management of hepatic hydrothorax.
Anand V. Kulkarni, Mithun Sharma, Pramod Kumar, Rajesh Gupta, Padaki Nagaraja Rao   +4 more
openaire   +2 more sources

Midodrine in end-stage heart failure [PDF]

BMJ Supportive & Palliative Care, 2020
It is estimated that 5% of patients with heart failure (HF) will progress to end-stage disease refractory to medical therapy and might require prolonged hospitalisation with inotropic support. We present the case of a patient with end-stage HF who was admitted with cardiogenic shock.
Ariel Gonzalez-Cordero, Stephanie Ortiz-Troche, Juan Nieves-Rivera, Marcel Mesa-Pabón, Hilton Franqui-Rivera   +4 more
openaire   +2 more sources

Midodrine for the Treatment of Intradialytic Hypotension

Nephron, 1997
Recurrent intradialytic hypotension is probably the most severely disabling feature in dialysis patients and the etiology is multifactorial. We assessed the efficacy and safety of midodrine, a selective alpha1-adrenergic pressor agent in 12 patients with recurrent intradialytic hypotension.
Chin-Chin Yang, Chi-Hsiang Yeh, Han-Ping Li, Paik-Seong Lim, Yok-Tuan Lim   +4 more
openaire   +3 more sources

Midodrine

Chest, 2013
Thoracic duct injury is a rare but serious complication following surgery of the neck or chest that leads to uncontrolled chyle leak. Conventional management includes drainage, nutritional modification, or aggressive surgical interventions such as thoracic duct ligation, flap coverage, fibrin glue, or talc pleurodesis; few successful medical ...
Heather Warren, Ali Salim, Douglas Z. Liou, Nicolas Melo, Eric J. Ley, Dermot P. Maher, Harmik J. Soukiasian   +6 more
openaire   +3 more sources